Figure 1. Patient Recruitment, Randomization, and Flow in the BETonMACE Trial of Apabetalone for Reduction of Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome and Type 2 Diabetes.

^aReasons for exclusion varied, primarily failure to return for randomization visit. Reasons for discontinuation were due to patient preference.